Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipients

Transplantation Proceedings

Volumn 41, Issue 7, 2009, Pages 2881-2883

  Sevmis, S ^a   Pehlivan, S ^a   Shabazov, R ^a   Karakayali, H ^a   Ozcay, F ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COUGHING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HEPATOBLASTOMA; HISTOLOGY; HUMAN; IMAGING; IN SITU HYBRIDIZATION; INTRAHEPATIC CHOLESTASIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVER TUMOR; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDIASTINUM MASS; MORTALITY; MYCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOLOGIST; SEPSIS; STOMACH ULCER; T CELL LYMPHOMA; TREATMENT INDICATION; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; SURVIVORS; TIME FACTORS; YOUNG ADULT;

EID: 70149109360     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.07.048     Document Type: Article

References (13)

1. Jain A., Nalesnik M., Reyes J., et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236 (2002) 429 discussion 436
2. Ben-Ari Z., Amlot P., Lachmanan S.R., et al. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 5 (1999) 184
3. Ganschow R., Schulz T., Meyer T., et al. Low incidence of posttransplant lymphoproliferative disease in children treated with low-dose immunosuppression after liver transplantation. Transplant Proc 34 (2002) 1961
4. Opelz G., and Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222
5. Muti G., Cantoni S., Oreste P., et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 87 (2002) 67
6. Domingo-Domènech E., de Sanjosé S., González-Barca E., et al. Post-transplant lymphomas: a 20-year epidemiologic, clinical and pathologic study in a single center. Haematologica 86 (2001) 715
7. Smets F., Vajro P., Cornu G., et al. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 69 (2000) 982
8. Guthery S.L., Heubi J.E., Bucuvalas J.C., et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 75 (2003) 987
9. Sokal E.M., Caragiozoglou T., Lamy M., et al. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 56 (1993) 1394
10. Lange D., Bechstein W.O., Blumhardt G., et al. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation. Transplant Proc 25 (1993) 1870
11. Praghakaran K., Wise B., Chen A., et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg Jan 34 (1999) 112 discussion 115
12. McCarthy M., Ramage J., McNair A., et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 27 (1997) 1015
13. Colombat P., Salles G., Brousse N., et al. Rituximab (anti- CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101